Congratulations to our H2i venture 20/20 OptimEyes Technologies on being named the winner of the 2025 Blue Ticket Competition, hosted by University of Toronto Mississauga’s SpinUp and Merck! This award provides important support as the company advances its platform for rethinking corneal drugs to improve outcomes in eye care.
As part of the Blue Ticket award, 20/20 OptimEyes will receive a one-year SpinUp membership, mentorship from Merck scientists and business leaders, and access to U of T’s research talent and network.
“Winning the Merck Blue Ticket is an important recognition for 20/20 OptimEyes and a strong signal of confidence in our vision. Access to the SpinUp community, with its lab space, equipment, and resources, will help us accelerate validation of our platform through new partnerships and scale our technology to the next level,” said Frances Lasowski, CEO of 20/20 OptimEyes Technologies. “Guidance and support from Merck give us the expertise to focus our efforts on the applications where our platform can make the greatest difference for patients’ lives.”
20/20 OptimEyes is advancing the development of a transformative drug in eye care aimed at providing more comfort for people living with glaucoma, dry eye, and other eye diseases.